Sort by
Refine Your Search
-
contribute to innovative research improving cancer patient outcomes. · Professional development support including conference attendance and publication opportunities. · Access to state
-
Pal, please visit here . For a complete list of Dr. Pal’s publications please visit here . As a successful candidate you will: · Develop and maintain clinical and translational research trials
-
small and long noncoding RNAs to the regulation of gene expression during development and functioning of the immune system. Besides being fundamentally important, this work can potentially shed light on
-
epidemiological methodologies to advance our understanding of the germline genetic risk, somatic drivers, and early-life origins of childhood leukemia, with the goal of developing strategies for disease prevention
-
successful candidate, you will: This project with Dr. Nagarajan Vaidehi involves developing and application of interpretable machine learning methods to uncover allosteric regulation of disordered regions in
-
Hope. To accelerate the development of new therapies, we leverage City of Hope’s unique in-house GMP manufacturing capabilities for cell therapy (CAR-T cells, stem cells, etc.), monoclonal antibodies
-
highly motivated postdoctoral fellow to study transcriptional regulation and RNA metabolism in normal development and human diseases, such as neurological disorder, immunology, and cancer. In particular
-
the Department of Hematological Malignancies Translational Science, Department of Pediatrics, and Gehr Family Center for Leukemia Research. You will directly work on the following projects: 1) Development
-
are working on this may be the perfect opportunity: 1. Development of cell-free DNA (mutation and methylation), RNA, and exosomal-based liquid assays for early cancer detection, prognosis, and predictive
-
studies. The lab focuses on mechanisms underlying human T-cell development and lymphoid leukemogenesis and the application of these mechanistic insights to the development of novel anti-cancer immunotherapy